Interferons News and Research

RSS

Impaired anti-inflammatory response plays role in pathology of type 2 diabetes

Type 2 diabetes is classified as a metabolic disorder, but a growing number of researchers are beginning to think of it also as a disease of the innate immune system. Inflammation, a key component of the early immune response, is chronically elevated in people with type 2 diabetes.

17 Jun 2007

Dealing with emerging diseases

The outbreak of severe acute respiratory syndrome (SARS) in 2002 was a loud wake-up call for researchers studying infectious diseases.

16 May 2007

Liver center leading record number of studies to tackle hepatitis C

While many research institutions are suffering from funding cuts, Drs. Bruce R. Bacon and Adrian M. Di Bisceglie are chugging away with their usual tenacity.

27 Apr 2007

Anadys Pharmaceuticals presents data showing ANA773 promotes anti-tumor activity of killer cells

Anadys Pharmaceuticals presented data from an in vitro study showing that the active metabolite of ANA773 promotes natural killer (NK) cell-mediated anti-tumor response by inducing cytokine secretion, cytolysis of tumor cells and enhanced antibody-dependent cellular cytotoxicity (ADCC), during a poster presentation at the Annual Meeting of the American Association of Cancer Research (AACR) in Los Angeles.

18 Apr 2007

Body uses a 'dual key' system to secure immune system

"Dual key" activation, in which two people must act in concert to launch a weapon, is often installed to safeguard highly destructive arms.

2 Apr 2007

Scientific breakthrough could mean greater protection for asthmatics

Colds are known to be a major trigger of asthma attacks and asthmatics are far more likely to suffer a severe attack during a cold and even end up being hospitalised.

From Asthma + Lung UK 14 Aug 2006

Pros and cons of starting multiple sclerosis treatment early

An editorial accompanying a published debate on the pros and cons of starting treatment early in the course of multiple sclerosis comes down in favor of early treatment for this potentially devastating disease.

23 May 2006

Atorvastatin could prove an effective therapy for multiple sclerosis

Scientists at the University of California, San Francisco and Stanford University Medical Center are reporting compelling new evidence that the cholesterol-lowering drug atorvastatin could prove an effective therapy for preventing the progression of, and reversing the severity of, multiple sclerosis (MS).

20 Mar 2006

Multikine treatment increases survival in cancer patients

CEL-SCI Corporation has announced positive results from a long-term follow-up study of head & neck cancer patients treated with its drug Multikine in a Phase II clinical trial.

21 Feb 2006

Another step forward in the battle against bacterial infections

Bacterial infections can strike anyone, and they can sometimes be fatal. Because more and more bacteria are becoming resistant to the pre-eminent remedy; antibiotics; the search for new remedies against bacterial infections is in high gear.

12 Feb 2006

Advance in the fight against bacterial infections

Bacterial infections can strike anyone, and they can sometimes be fatal. Because more and more bacteria are becoming resistant to the pre-eminent remedy - antibiotics - the search for new remedies against bacterial infections is in high gear.

2 Feb 2006

Discovery of molecular roots of asthma, arthritis, and multiple sclerosis

The molecular roots of inflammatory and autoimmune diseases such as asthma, arthritis, and multiple sclerosis (MS) have been discovered by a team of researchers led by The University of Texas M. D. Anderson Cancer Center. They say their findings may point to ways to effectively treat these diseases - if not stop them before they start.

4 Oct 2005

Greasing the gears that drive the interferon signal

Interferon -- a critical protein that mediates the body's defense against a wide variety of infectious agents and tumors -- may soon have greater therapeutic value as the result of a new study by researchers at Washington University School of Medicine in St. Louis.

3 Oct 2005

New Stat1 and interferon findings

By altering a molecule called Stat1, which is involved in cellular immune signaling, scientists have succeeded in making the molecule more responsive and thus more efficient. This old protein with a new twist may eventually be used to improve the body's defense against infection.

28 Sep 2005

Combination of ribavirin and interferon is more effective in treating hepatitis C than using interferon alone

The researchers reviewed 72 randomized trials and 9,991 patients who had chronic hepatitis C for more than six months and were previously untreated, who had relapsed after treatment or who had not responded to other treatment.

19 Jul 2005

Asthmatics naturally deficient in antiviral immunity

Asthmatics produce lower levels of a type of immune cell protein needed to fight off infection from colds and other viruses, scientists have discovered.

6 Apr 2005

Study reveals how brain's immune system fights viral encephalitis

The findings, published as the cover study in the latest issue of Virology, show that proteins in neurons fight the virus at multiple stages - by preventing the formation of viral RNA and proteins, and blocking the virus' release, which could infect other cells in the brain.

16 Mar 2005

Peginterferon alfa-2b produced sustained responses in patients with chronic hepatitis B

Results from a large international clinical study reported in this week's issue of The Lancet showed that peginterferon alfa-2b produced sustained responses in patients with chronic hepatitis B. The investigator-initiated study is the largest clinical trial to date with peginterferon alfa-2b therapy for chronic hepatitis B.

7 Jan 2005

No evidence that Glatiramer acetate slows multiple sclerosis progression

In this week's issue of the Lancet Neurology, glatiramer acetate, known as Copaxone(R), was subjected to an independent review. The systematic review, called a Cochrane Review, performed by Dr. Luca Munari and colleagues, challenges the claims of benefit from previous industry- based publications.

1 Nov 2004

A trial of beta-interferon-1a in inclusion-body myositis has failed to find benefit from the drug in this disease

A trial of beta-interferon-1a in inclusion-body myositis (IBM) has failed to find benefit from the drug in this disease. Beta-interferons counteract some of the activities of the immune system, which some experts believe is misguided in IBM.

5 Oct 2004